Novel roles of complement in renal diseases and their therapeutic consequences

Kidney International

Volumn 84, Issue 3, 2013, Pages 441-450

  Wada, Takehiko ^a   Nangaku, Masaomi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

alternative pathway; C3 glomerulopathy; complement activation; hemolytic uremic syndrome; ischemia reperfusion injury

Indexed keywords

ALKYLATING AGENT; CCX 168; COMPLEMENT; COMPLEMENT COMPONENT C5A RECEPTOR INHIBITOR; ECULIZUMAB; ENOXAPARIN; GLUCOCORTICOID; IMMUNOGLOBULIN; RECEPTOR BLOCKING AGENT; RITUXIMAB; UNCLASSIFIED DRUG;

ANCA ASSOCIATED VASCULITIS; ANTIBODY PRODUCTION; ARTICLE; C1 GLOMERULOPATHY; C3 GLOMERULONEPHRITIS; C3 GLOMERULOPATHY; CFHR5 NEPHROPATHY; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; COMPLEMENT SYSTEM; DENSE DEPOSIT DISEASE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; GENE MUTATION; GENETIC SCREENING; GLOMERULOPATHY; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INNATE IMMUNITY; KIDNEY DISEASE; KIDNEY INJURY; MEMBRANOUS GLOMERULONEPHRITIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; IMMUNITY, INNATE; KIDNEY DISEASES; MICE; RATS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 84883450056     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.134     Document Type: Short Survey

References (98)

1. Karsten CM, Pandey MK, Figge J et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nat Med 2012; 18: 1401-1406.
2. Naito AT, Sumida T, Nomura S et al. Complement C1q activates canonical Wnt signaling and promotes aging-related phenotypes. Cell 2012; 149: 1298-1313.
3. Sargsyan SA, Serkova NJ, Renner B et al. Detection of glomerular complement C3 fragments by magnetic resonance imaging in murine lupus nephritis. Kidney Int 2012; 81: 152-159.
4. Vizjak A, Ferluga D, Rozic M et al. Pathology, clinical presentations, and outcomes of C1q nephropathy. J Am Soc Nephrol 2008; 19: 2237-2244.
5. Mii A, Shimizu A, Masuda Y et al. Current status and issues of C1q nephropathy. Clin Exp Nephrol 2009; 13: 263-274.
6. Levy M, Gubler MC, Sich M et al. Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits (Type I MPGN). Clin Immunol Immunopathol 1978; 10: 477-492.
7. Habib R, Gubler MC, Loirat C et al. Dense deposit disease: A variant of membranoproliferative glomerulonephritis. Kidney Int 1975; 7: 204-215.
8. Strife CF, McEnery PT, McAdams AJ et al. Membranoproliferative glomerulonephritis with disruption of the glomerular basement membrane. Clin Nephrol 1977; 7: 65-72.
9. Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy: Resolving the confusion. Kidney Int 2012; 81: 434-441.
10. Fakhouri F, Fremeaux-Bacchi V, Noel LH et al. C3 glomerulopathy: A new classification. Nat Rev Nephrol 2010; 6: 494-499.
11. Servais A, Fremeaux-Bacchi V, Lequintrec M et al. Primary glomerulonephritis with isolated C3 deposits: A new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007; 44: 193-199.
12. Martinez-Barricarte R, Heurich M, Valdes-Canedo F et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 2010; 120: 3702-3712.
13. Sethi S, Gamez JD, Vrana JA et al. Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway. Kidney Int 2009; 75: 952-960.
14. Sethi S, Fervenza FC, Zhang Y et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 2011; 6: 1009-1017.
15. Zhang Y, Meyer NC, Wang K et al. Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol 2012; 7: 265-274.
16. Sethi S, Fervenza FC, Zhang Y et al. C3 glomerulonephritis: Clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 2012; 82: 465-473.
17. Servais A, Noel LH, Roumenina LT et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82: 454-464.
18. Walker PD, Ferrario F, Joh K et al. Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod Pathol 2007; 20: 605-616.
19. Nasr SH, Valeri AM, Appel GB et al. Dense deposit disease: Clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 2009; 4: 22-32.
20. Abrera-Abeleda MA, Nishimura C, Smith JL et al. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet 2006; 43: 582-589.
21. Paixao-Cavalcante D, Lopez-Trascasa M, Skattum L et al. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int 2012; 82: 1084-1092.
22. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: Pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol 2011; 31: 341-348.
23. Gale DP, de Jorge EG, Cook HT et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010; 376: 794-801.
24. Athanasiou Y, Voskarides K, Gale DP et al. Familial C3 glomerulopathy associated with CFHR5 mutations: Clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol 2011; 6: 1436-1446.
25. Malik TH, Lavin PJ, Goicoechea De Jorge E et al. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol 2012; 23: 1155-1160.
26. Bomback AS, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol 2012; 8: 634-642.
27. Bomback AS, Smith RJ, Barile GR et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7: 748-756.
28. Radhakrishnan S, Lunn A, Kirschfink M et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med 2012; 366: 1165-1166.
29. Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of densedeposit disease. N Engl J Med 2012; 366: 1163-1165.
30. Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense-deposit disease. N Engl J Med 2012; 366: 1161-1163.
31. McCaughan JA, O'Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: An emerging role for complementary therapies. Am J Transplant 2012; 12: 1046-1051.
32. Bagchus WM, Hoedemaeker PJ, Rozing J et al. Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies. A sequential histological and ultrastructural study in the rat. Lab Invest 1986; 55: 680-687.
33. Liu L, Qiu W, Wang H et al. Sublytic C5b-9 complexes induce apoptosis of glomerular mesangial cells in rats with Thy-1 nephritis through role of interferon regulatory factor-1-dependent caspase 8 activation. J Biol Chem 2012; 287: 16410-16423.
34. Zhang W, Lachmann PJ. Glycosylation of IgA is required for optimal activation of the alternative complement pathway by immune complexes. Immunology 1994; 81: 137-141.
35. Suzuki H, Kiryluk K, Novak J et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol 2011; 22: 1795-1803.
36. Oortwijn BD, Eijgenraam JW, Rastaldi MP et al. The role of secretory IgA and complement in IgA nephropathy. Semin Nephrol 2008; 28: 58-65.
37. Gharavi AG, Kiryluk K, Choi M et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011; 43: 321-327.
38. Stangou M, Alexopoulos E, Pantzaki A et al. C5b-9 glomerular deposition and tubular alpha3beta1-integrin expression are implicated in the development of chronic lesions and predict renal function outcome in immunoglobulin A nephropathy. Scand J Urol Nephrol 2008; 42: 373-380.
39. Espinosa M, Ortega R, Gomez-Carrasco JM et al. Mesangial C4d deposition: A new prognostic factor in IgA nephropathy. Nephrol Dial Transplant 2009; 24: 886-891.
40. Roos A, Rastaldi MP, Calvaresi N et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 2006; 17: 1724-1734.
41. Kerjaschki D. Pathomechanisms and molecular basis of membranous glomerulopathy. Lancet 2004; 364: 1194-1196.
42. Nangaku M, Shankland SJ, Couser WG. Cellular response to injury in membranous nephropathy. J Am Soc Nephrol 2005; 16: 1195-1204.
43. Cybulsky AV. Membranous nephropathy. Contrib Nephrol 2011; 169: 107-125.
44. Beck LH Jr, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11-21.
45. Remuzzi G, Chiurchiu C, Abbate M et al. Rituximab for idiopathic membranous nephropathy. Lancet 2002; 360: 923-924.
46. Ruggenenti P, Cravedi P, Chianca A et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23: 1416-1425.
47. Fervenza FC, Cosio FG, Erickson SB et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008; 73: 117-125.
48. Stuhlinger W, Kourilsky O, Kanfer A et al. Letter: Haemolytic-uraemic syndrome: Evidence for intravascular C3 activation. Lancet 1974; 2: 788-789.
49. Warwicker P, Goodship TH, Donne RL et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998; 53: 836-844.
50. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-1687.
51. Ferreira VP, Herbert AP, Cortes C et al. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol 2009; 182: 7009-7018.
52. Fremeaux-Bacchi V, Moulton EA, Kavanagh D et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2006; 17: 2017-2025.
53. Heinen S, Sanchez-Corral P, Jackson MS et al. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat 2006; 27: 292-293.
54. Skerka C, Jozsi M, Zipfel PF et al. Autoantibodies in haemolytic uraemic syndrome (HUS). Thromb Haemost 2009; 101: 227-232.
55. Dragon-Durey MA, Sethi SK, Bagga A et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010; 21: 2180-2187.
56. Thurman JM, Marians R, Emlen W et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4: 1920-1924.
57. Morigi M, Galbusera M, Gastoldi S et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 2011; 187: 172-180.
58. Zoja C, Locatelli M, Pagani C et al. Lack of the Lectin-like Domain of Thrombomodulin Worsens Shiga Toxin-Associated Hemolytic Uremic Syndrome in Mice. J Immunol 2012; 189: 3661-3668.
59. Reti M, Farkas P, Csuka D et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 2012; 10: 791-798.
60. Caprioli J, Noris M, Brioschi S et al. Genetics of HUS: The impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108: 1267-1279.
61. Goicoechea De Jorge E, Harris CL, Esparza-Gordillo J et al. Gain-offunction mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA 2007; 104: 240-245.
62. Fremeaux-Bacchi V, Miller EC, Liszewski MK et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008; 112: 4948-4952.
63. Zuber J, Fakhouri F, Roumenina LT et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8: 643-657.
64. Tsai HM. Excessive activation of the complement system in atypical hemolytic uremic syndrome: Is it ready for prime time? Kidney Int 2010; 77: 267-269.
65. Thurman JM. Therapeutic regulation of complement in patients with renal disease - where is the promise? Clin Nephrol 2012; 77: 413-423.
66. Lapeyraque AL, Malina M, Fremeaux-Bacchi V et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011; 364: 2561-2563.
67. Chapin J, Weksler B, Magro C et al. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2012; 157: 772-774.
68. Qin X, Goldfine A, Krumrei N et al. Glycation inactivation of the complement regulatory protein CD59: A possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes 2004; 53: 2653-2661.
69. Uesugi N, Sakata N, Nangaku M et al. Possible mechanism for medial smooth muscle cell injury in diabetic nephropathy: Glycoxidationmediated local complement activation. Am J Kidney Dis 2004; 44: 224-238.
70. Hansen TK, Forsblom C, Saraheimo M et al. Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes. Diabetologia 2010; 53: 1517-1524.
71. Woroniecka KI, Park AS, Mohtat D et al. Transcriptome analysis of human diabetic kidney disease. Diabetes 2011; 60: 2354-2369.
72. Franceschini N, Shara NM, Wang H et al. The association of genetic variants of type 2 diabetes with kidney function. Kidney Int 2012; 82: 220-225.
73. Sandholm N, Salem RM, McKnight AJ et al. New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet 2012; 8: E1002921.
74. Alkayyali S, Lajer M, Deshmukh H et al. Common variant in the HMGA2 gene increases susceptibility to nephropathy in patients with type 2 diabetes. Diabetologia 2013; 56: 323-329.
75. Wang H, Vinnikov I, Shahzad K et al. The lectin-like domain of thrombomodulin ameliorates diabetic glomerulopathy via complement inhibition. Thromb Haemost 2012; 108: 1141-1153.
76. Xiao H, Schreiber A, Heeringa P et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 2007; 170: 52-64.
77. Huugen D, van Esch A, Xiao H et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int 2007; 71: 646-654.
78. Xing GQ, Chen M, Liu G et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol 2009; 29: 282-291.
79. Gou SJ, Yuan J, Chen M et al. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int 2013; 83: 129-137.
80. Lyons PA, Rayner TF, Trivedi S et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012; 367: 214-223.
81. Matsuo S, Morita Y, Mizuno M et al. Proteinuria and damage to tubular cells-is complement a culprit? Nephrol Dial Transplant 1998; 13: 2723-2726.
82. Sheerin NS, Sacks SH. Chronic interstitial damage in proteinuria. Does complement mediate tubulointerstitial injury? Kidney Blood Press Res 1999; 22: 47-52.
83. Gaarkeuken H, Siezenga MA, Zuidwijk K et al. Complement activation by tubular cells is mediated by properdin binding. Am J Physiol Renal Physiol 2008; 295: F1397-F1403.
84. Siezenga MA, van der Geest RN, Mallat MJ et al. Urinary properdin excretion is associated with intrarenal complement activation and poor renal function. Nephrol Dial Transplant 2010; 25: 1157-1161.
85. Zaferani A, Vives RR, van der Pol P et al. Identification of tubular heparan sulfate as a docking platform for the alternative complement component properdin in proteinuric renal disease. J Biol Chem 2011; 286: 5359-5367.
86. Rodriguez-Iturbe B, Garcia Garcia G. The role of tubulointerstitial inflammation in the progression of chronic renal failure. Nephron Clin Pract 2010; 116: C81-c88.
87. Bao L, Wang Y, Haas M et al. Distinct roles for C3a and C5a in complement-induced tubulointerstitial injury. Kidney Int 2011; 80: 524-534.
88. Renner B, Coleman K, Goldberg R et al. The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells. J Immunol 2010; 185: 3086-3094.
89. Bao L, Wang Y, Chang A et al. Unrestricted C3 activation occurs in Crrydeficient kidneys and rapidly leads to chronic renal failure. J Am Soc Nephrol 2007; 18: 811-822.
90. Kitagawa K, Wada T, Furuichi K et al. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol 2004; 165: 237-246.
91. Zhou W, Farrar CA, Abe K et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000; 105: 1363-1371.
92. Thurman JM, Ljubanovic D, Royer PA et al. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest 2006; 116: 357-368.
93. Yamada K, Miwa T, Liu J et al. Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol 2004; 172: 3869-3875.
94. Turnberg D, Botto M, Lewis M et al. CD59a deficiency exacerbates ischemia-reperfusion injury in mice. Am J Pathol 2004; 165: 825-832.
95. Turnage RH, Magee JC, Guice KS et al. Complement activation by the hydroxyl radical during intestinal reperfusion. Shock 1994; 2: 445-450.
96. Renner B, Ferreira VP, Cortes C et al. Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Int 2011; 80: 165-173.
97. Peng Q, Li K, Smyth LA et al. C3a and c5a promote renal ischemiareperfusion injury. J Am Soc Nephrol 2012; 23: 1474-1485.
98. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012; 8: 622-633.